Endocyte Reports Second Quarter Financial Results and Provides Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
July 30, 2014 2:49 PM EDTChardan Capital affirms Endocyte (Nasdaq: ECYT) at Buy with a price target of $15 following Q2 results and updated information of EC1456.
Analyst Ling Wang commented, ECYT reported 2Q14 EPS of $0.54, vs. consensus... More



